Tubulis

Series-B+ Acquired by Gilead Sciences
tubulis.com Biotech & Healthcare Founded 2019 101-250
Total Funding $573M
Latest Round $360M Series-B+
Last Announced Oct 16, 2025
Investors 17 Backers
Decision Makers 6 Verified

About Tubulis

Tubulis develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company creates protein-drug conjugates with improved delivery, reduced toxicity, and enhanced therapeutic potential. Tubulis advances a pipeline of experimental drug candidates and collaborates with industry partners to expand oncology treatments. Its customers are partners and patients.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B+
Global Headquarters Undisclosed
Year Founded 2019
Team Size 101-250
Corporate Status Acquired by Gilead Sciences
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website tubulis.com
Domain Registered Date Aug 2, 2015

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

6 Events
  1. Capital Raise

    Raised $360,000,000 · Series-B+

    startupintros.com

  2. Capital Raise

    Raised $138,000,000 · Series-B+

  3. Capital Raise

    Raised $63,000,000 · Series-B+

  4. Capital Raise

    Raised $12,000,000 · Series-A

    startupintros.com

  5. Milestone

    Company founded

  6. Milestone

    Website domain registered

    tubulis.com

Investors & Backers

17
Andera Partners
Bayern Kapital
BioMedPartners
coparion
Deep Track Capital
EQT Life Sciences
Evotec
Fidelity
Frazier Life Sciences
Fund+
HTGF
Janus Henderson Investors
Nextech Invest
OCCIDENT
Seventure Partners
Venrock Healthcare Capital Partners
Wellington Management

Funding History

4 Rounds
Series-B+ · Oct 16, 2025
$360,000,000 startupintros.com
Series-B+ · Mar 14, 2024
$138,000,000 Source
Series-B+ · May 3, 2022
$63,000,000 Source
Series-A · Jul 1, 2020

Founders & Leadership

5

Björn Hock

Chief Development Officer

Work email & phone locked Unlock →

Christian Hackenberger

scientific co-founder

Work email & phone locked Unlock →

Dominik Schumacher

co-founder

Work email & phone locked Unlock →

Ingo Lehrke

CBO

Work email & phone locked Unlock →

Jonas Helma-Smets

CSO & Co-Founder

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts